Seminars in Pediatric Surgery
Volume 16, Issue 3 , Pages 146-153 , August 2007

Progress in basic inflammatory bowel disease research

  • Subra Kugathasan, MD

      Affiliations

    • Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Claudio Fiocchi, MD

      Affiliations

    • Department of Pathobiology, and Department of Gastroenterology and Hepatology, The Cleveland Clinic, Cleveland, Ohio.
    • Corresponding Author InformationAddress reprint requests and correspondence: Claudio Fiocchi, MD, Department of Pathobiology, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195.

References 

  1. Cobrin GM, Abreu MT. Defects of mucosal immunity leading to Crohn’s disease. Immunol Rev. 2005;206:277–295
  2. Targan SR, Karp LC. Defects of mucosal immunity leading to ulcerative colitis. Immunol Rev. 2005;206:296–305
  3. Bousvaros A, Sylvester F, Kugathasan S, et al. Challenges in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:886–913
  4. Cohen ML. Changing patterns of infectious disease. Nature. 2000;406:762–767
  5. Ouyang Q, Tandon R, Goh K-L, et al. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol. 2005;21:408–413
  6. Bach J-F. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med. 2002;347:911–920
  7. Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmunity Rev. 2004;3:390–400
  8. Thomas GAO, Rhodes J, Green JT. Inflammatory bowel disease and smoking: a review. Am J Gastroenterol. 1998;93:144–149
  9. Timmer A, Sutherland LR, Martin F. Oral contraceptive use and smoking are risk factors for relapse of Crohn’s disease. Gastroenterology. 1998;114:1143–1150
  10. Rutgeerts P, D’Haens G, Hiele M, et al. Appendectomy protects against ulcerative colitis. Gastroenterology. 1994;106:1251–1253
  11. Andersson RE, Olaison G, Tysk C, et al. Appendectomy is followed by increased risk of Crohn’s disease. Gastroenterology. 2003;124:40–46
  12. Hugot J-P, Chamaiilard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411:599–603
  13. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in Nod2 associated with susceptibility to Crohn’s disease. Nature. 2001;411:603–606
  14. Chamaillard M, Iacob R, Desreumaux P, et al. Advances and perspectives in the genetics of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:143–151
  15. Giallourakis C, Stoll M, Miller K, et al. IBD5 is a general risk factor for inflammatory bowel disease: replication of association with Crohn disease and indentification of a novel association with ulcerative colitis. Am J Hum Genet. 2003;73:205–211
  16. Negoro K, McGovern DP, Kinouchi Y, et al. Analysis of the IBD5 locus and potential gene-gene interactions in Crohn’s disease. Gut. 2003;52:541–546
  17. Babusukumar U, Wang T, McGuire E, et al. Contribution of OCTN variants within the IBD5 locus to pediatric onset Crohn’s disease. Am J Gastroenterol. 2006;101:1–8
  18. Stoll M, Corneliussen B, Costello CM, et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet. 2004;36:476–480
  19. Friedrichs F, Brescianini S, Annese V, et al. Evidence of transmission ratio distortion of DLG5 R30Q variant in general and implication of an association with Crohn disease in men. Hum Genet. 2006;119:305–311
  20. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resitance gene, mdr1a, spontaneously develop colitis. J Immunol. 1998;161:5733–5744
  21. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314:1461–1463
  22. Becker C, Wirtz S, Blessing M, et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest. 2003;112:693–706
  23. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715–725
  24. Abreu MT, Taylor KD, Ling YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn’s disease. Gastroenterology. 2002;123:679–688
  25. Kugathasan S, Collins N, Maresso K, et al. CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn’s disease. Clin Gastroenterol Hepatol. 2004;2:1003–1009
  26. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005;307:731–734
  27. Chiodini RJ, Kruiningen HJV, Thayer WR, et al. Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified Mycobacterium species isolated from patients with Crohn’s disease. Dig Dis Sci. 1984;29:1073–1079
  28. Thomas GAO, Swift GL, Green JT, et al. Controlled trial of antituberculous chemotherapy in Crohn’s disease: a five year follow up study. Gut. 1998;42:497–500
  29. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn’s disease. Gastroenterology. 1998;115:1405–1413
  30. Wakefield AJ, Pittilo RM, Sim R, et al. Evidence of persistent measles virus infection in Crohn’s disease. J Med Virol. 1993;39:345–353
  31. Ekbom A, Daszak P, Kraaz W, et al. Crohn’s disease after in-utero measles virus exposure. Lancet. 1996;348:515–517
  32. MacDonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005;307:1920–1925
  33. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495–549
  34. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44–54
  35. D’Haens G, Geboes K, Peeters M, et al. Early lesions caused by infusion of intestinal contents in excluded ileum of Crohn’s disease. Gastroenterology. 1998;114:262–267
  36. Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative?. Gastroenterology. 1999;116:1246–1260
  37. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology. 2005;128:2020–2028
  38. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but it is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol. 1995;102:448–455
  39. Kelly D, Conway S, Aminov R. Commensal gut bacteria: mechanisms of immune modulation. Trends Immunol. 2005;26:326–333
  40. Girardin SE, Hugot J-P, Sansonetti PJ. Lessons from Nod2 studies: towards a link between Crohn’s disease and bacterial sensing. Trends Immunol. 2003;24:652–658
  41. Fiocchi C. The normal intestinal mucosa: a state of “controlled inflammation.”. In:  Targan SR,  Shanahan F editor. Inflammatory Bowel Disease (From Bench to Bedside). (2nd ed.). Dordrecht: Kluwer Academic Publishers; 2003;p. 101–120
  42. Hisamatsu T, Suzuki M, Reinecker H-C, et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology. 2003;124:993–1000
  43. Staag AJ, Hart AL, Knight SC, et al. The dendritic cell: its role in intestinal inflammation and relationship with gut bacteria. Gut. 2003;52:1522–1529
  44. Hart AL, Al-Hassi HO, Rigby RJ, et al. Characteristics of intestinal dendritic cells in inflammatory bowel disease. Gastroenterology. 2005;129:50–65
  45. Wehkamp J, Harder J, Weichenthal M, et al. NOD2(CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression. Gut. 2004;53:1658–1664
  46. Wehkamp J, Harder J, Weichenthal M, et al. Inducible and constitutive β-defensins are differentially expressed in Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2003;9:215–223
  47. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol. 2004;5:975–979
  48. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118:229–241
  49. Cario E, Podolsky DK. Differential alterationin intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun. 2000;68:7010–7017
  50. Franchimont D, Vermeire S, ElHousni H, et al. Deficient host-bacteria interactions in inflammatory bowel disease? (The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn’s disease and ulcerative colitis). Gut. 2004;53:987–992
  51. Torok H-P, Glas J, Tonenchi L, et al. Crohn’s disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology. 2004;127:365–366
  52. Li J, Moran T, Swanson E, et al. Regulation of IL-8 and IL-1β expression in Crohn’s disease associated with NOD2/CARD15 mutations. Hum Mol Genet. 2004;13:1715–1725
  53. van Heel DA, Gosh S, Butler M, et al. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn’s disease. Lancet. 2005;365:1794–1796
  54. Takahashi F, Das KM. Isolation and characterization of a colonic autoantigen specifically recognized by colon tissue-bound immunoglobulin G from idiopathic ulcerative colitis. J Clin Invest. 1985;76:311–318
  55. Podolsky DK, Fiocchi C. Cytokines, chemokines, growth factors, eicosanoids and other bioactive molecules in IBD. In:  Kirsner JB editors. Inflammatory Bowel Disease. Philadelphia, PA: W.B. Saunders; 1999;p. 191–207
  56. Neurath MF, Weigmann B, Finotto S, et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn’s disease. J Exp Med. 2002;195:1129–1143
  57. Monteleone G, Biancone L, Marasco R, et al. Interleukin 12 is expressed and actively released by Crohn’s disease intestinal lamina propria mononuclear cells. Gastroenterology. 1997;112:1169–1178
  58. Pizarro TP, Michie MH, Bentz M, et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn’s disease: expression and localization in intestinal mucosal cells. J Immunol. 1999;162:6829–6835
  59. Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn’s disease T-cells to multiple apoptotic stimuli is associated with a Bcl-2/Bax mucosal imbalance. J Immunol. 1999;163:1081–1090
  60. Sturm A, Leite AZ, Danese S, et al. Divergent cell cycle kinetic sunderlie the distinct functional capacity of mucosal T-cells in Crohn’s disease (CD) and ulcerative colitis (UC). Gut. 2004;53:1624–1631
  61. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria lymphokine secretion profiles in inflammatory bowel disease (Crohn’s disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5). J Immunol. 1996;157:1261–1270
  62. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004;113:1490–1497
  63. Weaver CT, Harrington LE, Mangan PR, et al. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity. 2006;24:677–688
  64. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest. 2006;116:1218–1222
  65. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116:1310–1316
  66. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52:65–70
  67. Maul J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory CD4+CD25+high T cells in inflammatory bowel disease. Gastroenterology. 2005;128:1868–1878
  68. Makita S, Kanai T, Oshima S, et al. CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol. 2004;173:3119–3130
  69. Selby WS, Janossy G, Mason DY, et al. Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease. Clin Exp Immunol. 1983;53:614–618
  70. Mayer L, Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J Clin Invest. 1990;86:1255–1260
  71. Nakazawa A, Dotan I, Brimnes J, et al. The expression and function of costimulatory molecules B7h and B7-H1 on colonic epithelial cells. Gastroenterology. 2004;126:1347–1357
  72. Baugh MD, Perry MJ, Hollander AP, et al. Matrix metalloproteinases levels are elevated in inflammatory bowel disease. Gastroenterology. 1999;117:814–822
  73. Monteleone G, MacDonald TT, Wathen NC, et al. Enhancing lamina propria Th1 cell responses with interleukin 12 produces severe tissue injury. Gastroenterology. 1999;117:1069–1077
  74. Vogel JD, West GA, Sturm A, et al. CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokines causing T-cell transmigration. Gastroenterology. 2004;126:63–80
  75. Binion DG, West GA, Volk EE, et al. Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet. 1998;352:1742–1746
  76. Binion DG, Rafiee P, Ramunujam KS, et al. Deficient iNOS in inflammatory bowel disease intestinal microvascular endothelial cells results in increased leukocyte adhesion. Free Radical Biol Med. 2000;29:881–888
  77. Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol. 2004;25:489–495
  78. Danese S, Katz JA, Saibeni S, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut. 2003;52:1435–1441
  79. Danese S, delaMotte C, Sturm A, et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology. 2003;124:1249–1264
  80. Danese S, Sans M, delaMotte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology. 2006;130:2060–2073
  81. Korzenik JR. Past and current theories of etiology of IBD (Toothpaste, worms, and refrigerators). J Clin Gastroenterol. 2005;39(suppl 2):S59–S65
  82. Rogler G. Update in inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol. 2004;20:311–317
  83. Rufo PA, Bousvarors A. Current therapy of inflammatory bowel disease in children. Pediatr Drugs. 2006;8:279–302
  84. Sandborn WJ, Targan SR. Biological therapy of inflammatory bowel disease. Gastroenterology. 2002;122:1592–1608
  85. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel disease: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004;126:1620–1633

PII: S1055-8586(07)00021-2

doi: 10.1053/j.sempedsurg.2007.04.002

Seminars in Pediatric Surgery
Volume 16, Issue 3 , Pages 146-153 , August 2007

Article Tools